3Vote!
Radon Mitigation Pittsburgh (Free subscription) | yesterday
( EMAILWIRE.COM , November 06, 2009 ) Del Mar, CA - With AirStar International having recently committed to a working relationship with Aero Deportes, which will use AirStar technology to assist with the filming of upcoming movies and to capture aerial footage of marathons and soccer matches within Ecuador, the continuing demand for cost effective technology is evident. AirStar, a subsidiary of Mundus,...
Explore : Channels,
Discovery,
Drug Manufacturers,
Ecuador,
Engineering,
Equipment,
Health Industries,
i-Remote,
Motorola,
Pfizer Inc.,
Remote Control,
Research In Motion,
South America,
Telecommunication,
Telecommunication Companies,
Twitter
5Vote!
Medical News Today (Free subscription) | 05/11/2009
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD).
3Vote!
Radon Mitigation Pittsburgh (Free subscription) | 05/11/2009
( EMAILWIRE.COM , November 04, 2009 ) Del Mar, CA Mundus Group, Inc. have only begun to tap into their vast growth potential and the development of their professional and commercial demand base with its announcement of new division AirStar Foto Worx. AirStar Foto Worx will continue use of Unmanned Aircraft Vehicles (UAV) for professional aerial photography sales and service. This division will have...
Explore : Activision,
Drug Manufacturers,
Equipment,
Health Industries,
Money,
Motorola,
New York Stock Exchange,
Norfolk Southern,
Pfizer Inc.,
Railroads,
Stock exchange,
Telecommunication,
Transportation,
Twitter,
Video Games Industry
3Vote!
Business Wire (Free subscription) | 03/11/2009
NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD). The CONTACT study will assess as primary endpoints the potential benefits of adding dimebon to...
3Vote!
Business Wire (Free subscription) | 22/10/2009
NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 16-cent fourth-quarter 2009 dividend on the company’s common stock, payable December 1, 2009, to shareholders of record at the close of business on November 6, 2009. The fourth-quarter 2009 cash dividend will be the 284th consecutive quarterly dividend paid by Pfizer.
3Vote!
Indian Express (Free subscription) | 20/10/2009
Pfizer Inc, the world's biggest drugmaker, said third-quarter profit rose 26%, beating analysts' estimates, as it fired workers to cut costs.
3Vote!
Daily News Analysis (Free subscription) | 20/10/2009
Pfizer's bought Wyeth to help soften the 2011 blow from the loss of U.S. patent protection on the cholesterol drug Lipitor -- the world's biggest-selling prescription medicine.
3Vote!
Reuters (Free subscription) | 20/10/2009
NEW YORK (Reuters) - Pfizer Inc reported higher third-quarter profit as aggressive cost-cutting helped offset unfavorable foreign currency exchange rates and declining sales of drugs, including those facing competition from cheaper generics.
3Vote!
iStockAnalyst.com (Free subscription) | 19/10/2009
Pfizer Inc (PFE), the world's largest drug company, is scheduled to report their third quarter results on Tuesday, October 20, 2009. [More...]
3Vote!
IP Lab Blog (Free subscription) | 18/10/2009
NEW YORK - Pfizer Inc announced in a press release that it has combined operations with Wyeth following the closing of the acquisition on October 15, 2009. Pfizer is now a more diversified health care company, with product offerings in human, animal, and c... (source: AG IP News) - RSS news feeds and Widgets on Feedzilla.com
3Vote!
The Earth Times Online Newspaper (Free subscription) | 17/10/2009
PHILADELPHIA - Pfizer Inc announced today that 24-week data from two clinical studies of the oral JAK inhibitor, CP-690,550, confirmed statistically significant ACR20 response and DAS28 remission rates for several doses versus placebo when given alone or in combination with methotrexate for
3Vote!
Business Wire (Free subscription) | 17/10/2009
PHILADELPHIA--(BUSINESS WIRE)--Pfizer Inc announced today that 24-week data from two clinical studies of the oral JAK inhibitor, CP-690,550, confirmed statistically significant ACR20 response and DAS28 remission rates for several doses versus placebo when given alone or in combination with methotrexate for patients with active rheumatoid arthritis (RA). The findings, which were presented this week...
3Vote!
The News Market (Free subscription) | 16/10/2009
Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with
3Vote!
Business Wire (Free subscription) | 16/10/2009
NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets. It has medicines in...
Videos